Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  

Journal InfoeISSN: 2251-7308 
pISSN: 2228-5881 
Freq.: Quarterly
Quick linkEditorial Board 
Aims and Scope
Online Submission
IssuesAll issues (TOC)
Current Issue
Articles in Press


Powered by

Advanced Pharmaceutical Bulletin (APB) is a peer-reviewed multidisciplinary international open access journal, covering a wide range of various integrative fields with Pharmaceutical sciences.
APB is the official journal of Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences (the 2nd largest university in Iran). 
Publication Advantages in Advanced Pharmaceutical Bulletin are: 
  • Free of charge publication for all types of articles
  • Fast and constructive peer review
  • Easy and quick online submission of manuscripts
  • Author friendly review 
  • Rapid publication by means of running issue concept, which gives authors the benefit of 'No Waiting Time' for the officially accepted manuscripts
  • Free publication of color images 
  • Worldwide visibility of papers (Open Access Journal)
  • Annual Award

Aims and Scopes
Advanced Pharmaceutical Bulletin (APB) is a peer-reviewed, open access journal that publishes original research papers, scientific commentaries, views and review articles, and editorial commentary. The area of focus is concepts in basic pharmaceutical science (physical, chemical, biological, clinical, socioeconomic-pharmacoeconomic, and regulatory aspects) including pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, immune-pharmaceuticals, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery.

- Formulation development studies are only acceptable if they provide a clear advancement in the field. Applying known formulation techniques to another drug does not suffice.
- A study of natural products will not be accepted if it only reports the pharmacological data of a certain plant or plant extracts. Identification and separation of potential active ingredients coupled with carefully planned pharmacological studies may be acceptable.
- Medicinal chemistry papers will be considered if new classes of drugs are studied or if there is a reasonable rationale for developing a new derivative of an old drug. Clear identification and separation of the compounds are needed. Mere synthesis of another derivative will not suffice.
- Routine bioequivalence studies, i.e., a comparison of the bioavailability of two or more products, will not be accepted for publication.
- Analytical method development for formulations will not be acceptable unless it contains experiments with sufficient scientific rigor and breakthrough data.

 Indexing Info:



A: 381 cites to articles published in 2014-2015 (during 2016)
B: 183 articles published in 2014-2015



 Chemical Abstracts Service

Chemical Abstracts 






 SCImago Journal & Country Rank








Press Manuscript Online. Powered by MAADRAYAN